Abstract
|
Association of XPC Gene Polymorphisms with Prostate Cancer Risk
by Shima A. Kahnamouei, Behzad Narouie, Mehdi Sotoudeh, Mohammad J. Mollakouchekian, Nasser Simforoosh, Seyed A. M. Ziaee, Mohammad Samzadeh, Mahdi Afshari, Seyed H. Jamaldini, Mahdieh Imeni, Mandana Hasanzad
|
|
|
Background: Defective DNA repair capacity caused by inherited polymorphisms could be associated with cancer susceptibility. One of the major repair pathways is Nucleotide Excision Repair (NER). We investigated Xeroderma Pigmentosum complementation group C (XPC) polymorphisms (Lys939Gln, PAT) with the risk of prostate cancer.
Methods: 154 confirmed prostate cancer patients and 205 Benign Prostate Hyperplasia (BPH) controls were recruited in this survey. The genotypes were determined by PCR-Restriction Fragment Length Polymorphism (RFLP) method.
Results: Our results indicated that there were no significant differences between the BPH group and patient group for the XPC Lys939Gln in this pathway. However, deletion/insertion (D/I) and insertion/insertion (I/I) of XPC PAT polymorphism in this pathway could decrease the risk of prostate cancer and act as a protective factor.
Conclusions: In this study, XPC Lys939Gln gene polymorphism was not associated with the risk of developing prostate cancer in Iranian patients. There are no association between different alleles of this polymorphism and grades and stages of tumors, but our results indicated the significant association between XPC PAT and reduction of prostate cancer risk in this group of patients. For more significant results, further samples are required.
DOI: 10.7754/Clin.Lab.2015.150914
|
